PELVIDOL IS A FOOD SUPPLEMENT TARGETED AGAINST CHRONIC PELVIC PAIN (CPP)

What does it prevent?

  • Dysmenorrhea
  • Premenstrual syndrome
  • Vulvodynia and dyspareunia
  • Painful bladder syndrome
  • Uterine cramping after invasive procedures (chorionic villus sampling and amniocentesis)

One tablet every 12 hours in case of pelvic pain, dysmenorrhea, dyspareunia, vulvodynia. Pain Relief already after 1-3 weeks of treatment.

Main causes of Chronic Pelvic Pain

Adolescence

  • Polycystic ovary syndrome (PCOS)
  • Endometriosis
  • Pelvic inflammatory disease
  • Vaginismus
  • Vulvo-vaginitis
  • Irritable bowel syndrome

Fertile age

  • Endometriosis
  • Pelvic inflammatory disease
  • Pelvic adherence syndrome
  • Vulvodynia
  • Dyspareunia
  • Uterine fibroids
  • Pelvic varicose veins

Pregnancy

  • Uterine hypercontractility
  • Phlogosis of urinary tract
  • Pelvic adherent syndrome
  • Endometriosis
  • Symphysis pubis dysfunction (SPD)
  • Coccydynia
  • Constipation
  • Anal fissures

 

Menopause

  • Urogenital prolapse
  • Pelvic varicose veins
  • Muscoloskeletal disorders
  • Diverticulitis
  • Painful bladder syndrome
  • Constipation
  • Anal fissures
  • Pelvis adherence syndrome

 

Active principles 1 tablet contains
PEA 300 mg
Magnesium 241,2 mg
Palmitoylethanolamide (PEA), the palmitic acid amide with ethanolamine is an active ingredient that can be found in food such as eggs, peanuts, peas, tomatoes, soy etc, and it is also produced by many cells of our body. It is highly concentrated in the brain tissue and it is synthesized by lipid components of the cellular membranes. Thus, PEA is an endogenous factor which is produced if needed to relieve inflammation and restore damaged tissues functionality. The mechanism of action of palmitoylethanolamide is to suppress a receptor situated in the nucleus of our cells, the peroxisome proliferator-activated receptor (PPAR-a) which operates a signal transduction to perform a variety of functions related to chronic inflammation and to algogenic transmission in neuropathic and pelvic pain.
Magnesium is an essential mineral, cofactor in over 300 enzymatic reactions. · Co-enzymatic action It modulates the tone and contractility of the smooth muscle fibers of the vessel wall interacting with calcium ions; it is a co-modulator of arterial pressure and it is the major determinant of glucose and insulin metabolism. It promotes the transmission of nerve stimuli to the muscles, it eases the assimilation of the vitamins of group B, C and E, moreover it stimulates the vitamin D synthesis and contributes to the solidity of the bones, as well as to the efficiency of the immune system. Administered in the form of salt, magnesium at high doses reduces uterine contractility both interfering with the nervous transmission mechanism and reducing the intracellular calcium concentration, essential for the contraction of smooth muscle fiber. · Analgesic action and mood stabilizing A good level of magnesium is important both to relieve menstrual pains and to reduce mood swings and irritability that are typical of premenstrual syndrome. In menopause, reduces heat flushes, decreases the anxious manifestations, prevents the appearance of osteoporosis and arthrosis from loss of mineral salts. Absorbed through the intestine, magnesium regulates its activity, countering symptoms of irritable bowel syndrome. Moreover, being alkalizing, it rebalances digestion, counteracting acidity and rebalancing the pH of the blood, with a beneficial anti-inflammatory effect.

Pelvidol is a food supplement containing alpha-lipoic acid and magnesium, specifically developed to fight chronic pelvic pain (chronic pelvic pain, CPP).
Pain, especially chronic, is a challenge to personal and relational balance and when it affects a woman it has implications not only on her gynecological and sexual but also procreative health. At the origin of CPP there is a comorbidity condition between different types of pain (urological, gynecological, sexual, colon-proctological, neuro-muscular) associated with a dysregulation of the somato-sensory system of the pelvic area. Women who suffer from this syndrome have often manifestations of anxiety and / or depression with limitations in social and sexual life.
The physical pain is subtended by an inflammatory and tissue process and it concerns mechanisms of the peripheral and central nervous system.
Alongside centrally acting analgesics and anti-inflammatories, some active ingredients of natural origin can effectively act on the pathogenetic process, as demonstrated by an extensive scientific documentation.
Pelvidol contains 600 mg of Alpha-Lipoic Acid which is very effective in the treatment of chronic pelvic and neuropathic pain thanks to its anti-oxidant, anti-inflammatory and neuroprotective activity. In the woman in fertile age it has shown an important beneficial effect in reducing dyspanuria, vulvodynia, painful bladder syndrome and the hypertonia of the pelvic floor. In women in menopause, supplementation with alpha-lipoic acid has multiple purposes: it is able to perform protective effects on the cardiovascular, nervous, neurosensory and bone levels.
The use of ALA for the treatment of pain in pregnancy is spreading and in vitro studies have documented an anti-inflammatory action on the placenta, with a significant reduction of the pro-inflammatory effects of thrombin in an experimental model that mimics the conditions of preterm rupture of the membranes.
Pelvidol contains 240 mg of Magnesium, whose supplementation helps to counter neuropsychic disorders (anxiety, distress, irritability, fall of mood, emotionality, insomnia, exasperation of PMS), neurovegetative somatizations (tachycardia, dyspnea, extrasystoles, vasoconstriction / hypertension, pallor, flushing, gastrointestinal symptoms, aerophagia, meteorism) and neuromuscular manifestations (cramps, paresthesias, myalgias, physical fatigue, muscular asthenia). It is useful also in pregnancy to prevent uterine hypercontractility.

Fig. 1 Neurobiology of chronic pelvic pain.
The CPP is due to 3 main mechanisms that are not mutually exclusive:
1. Nociceptive pain: it originates from peripheral damage or inflammation of the tissue of somatic or visceral structures, often due to mechanical causes.
2. Peripheral neuropathic pain: it originates from an intrinsic dysfunction of the PNS, which exacerbates stimuli also of low intensity.
3. Central neuropathic pain: it originates from a direct facilitatory modulation of the incoming nociceptive pathways.
  1. Engeler D, A.P. Baranowski, J. Borovicka, A. Cottrell, P. Dinis-Oliveira, S. Elneil, J. Hughes, E.J. Messelink, A. van Ophoven, Y. Reisman, A.C. de C. Williams Guidelines on Chronic Pelvic Pain. European Association of Urology, 2014
  2. Royal College of Obstetricians and Gynaecologists. Therapies Targeting the Nervous System for Chronic Pelvic Pain Relief. Scientific Impact Paper No. 46. January 2015
  3. Gomes MB, Negrato CA.. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr. 2014 Jul 28;6(1):80
  4. Moura FA, de Andrade KQ, Dos Santos JC, Goulart MO. Lipoic Acid: its Antioxidant and Anti-Inflammatory Role and Clinical Applications. Curr Top Med Chem. 2015 Jan 14 [Epub ahead of print].
  5. Graziottin A. Acido alfa lipoico: farmacologia e indicazioni cliniche. In Graziottin A (a cura di) Atti del Congresso “Menopausa precoce: dal dolore alla salute”, pag. 131-146, 2015, Fondazione Graziottin per la cura del dolore nella donna Onlus
  6. Di Tucci C, Di Feliciantonio M, Vena F, Capone C, Schiavi MC, Pietrangeli D, Muzii L, Benedetti Panici P. Alpha lipoic acid in obstetrics and gynecology. Gynecol Endocrinol. 2018 Sep; 34(9):729-733. doi: 10.1080/09513590.2018.1462320. Epub 2018 May 4.
  7. Gröber U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients. 2015 Sep; 7(9): 8199–8226.